Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

15.4%

8 terminated/withdrawn out of 52 trials

Success Rate

68.0%

-18.5% vs industry average

Late-Stage Pipeline

8%

4 trials in Phase 3/4

Results Transparency

65%

11 of 17 completed trials have results

Key Signals

17 recruiting11 with results7 terminated

Enrollment Performance

Analytics

N/A
19(40.4%)
Phase 1
16(34.0%)
Phase 2
7(14.9%)
Phase 3
2(4.3%)
Phase 4
2(4.3%)
Early Phase 1
1(2.1%)
47Total
N/A(19)
Phase 1(16)
Phase 2(7)
Phase 3(2)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (52)

Showing 20 of 52 trials
NCT04015700Phase 1Active Not Recruiting

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Role: collaborator

NCT06636162Early Phase 1Recruiting

Window of Opportunity Study of DSP-0390 in Gliomas

Role: collaborator

NCT04849871Not ApplicableActive Not Recruiting

Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma

Role: collaborator

NCT05111353Phase 1Completed

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery

Role: collaborator

NCT05743595Phase 1Active Not Recruiting

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Role: collaborator

NCT05187182Phase 1Recruiting

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Role: collaborator

NCT07379125Phase 1Not Yet Recruiting

Therapeutic RSK1 Targeting in Myelofibrosis

Role: collaborator

NCT07126158Phase 2Recruiting

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Role: collaborator

NCT05837455Phase 2Recruiting

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Role: collaborator

NCT07052305Phase 1Recruiting

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Role: collaborator

NCT07283783Not ApplicableRecruiting

INCLUDE Program: A Perioperative Wellness Program Tailored for Black Surgical Patients

Role: collaborator

NCT06636149Not ApplicableRecruiting

Maternal Maneuvers During Prolonged Labor

Role: collaborator

NCT05505643Not ApplicableRecruiting

Cryoablation vs Lumpectomy in T1 Breast Cancers

Role: collaborator

NCT04354064Recruiting

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Role: collaborator

NCT05944562Phase 1Active Not Recruiting

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

Role: collaborator

NCT04975139Recruiting

Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks

Role: collaborator

NCT05044039Phase 1Active Not Recruiting

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Role: collaborator

NCT07355205Phase 2Not Yet Recruiting

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Role: collaborator

NCT03687957Phase 1Active Not Recruiting

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

Role: collaborator

NCT05975593Not ApplicableRecruiting

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

Role: collaborator